Safety, Tolerability, and Immunogenicity of GC3106 (Quadrivalent Cell-culture Based Influenza Vaccine)

Inclusion Criteria: * Given written informed consent * Healthy Korean adults (age: between over 19 and under 65) * Korean adults who agree with 21 days follow up after vaccination and good compliance to study procedures * Those who are able to comply with the requirements for the study Exclusion Criteria: * Inability in written/verbal communication * Subjects who have participated in other interventional study within 30 days * Alcohol or drug abuse within 6 months * Heavy drinkers or subjects who do not agree to stop drinking for 3 days before vaccination and other 3 days after vaccination * Who got the treatment of psychotropic drugs and narcotic analgesic drugs within 6 months of enrollment * Hypersensitivity with drug or active ingredient * Disorders in immune function * History of Guillain-Barré syndrome * Disease/medications which are likely to cause any severe bleeding * Active infection or experience of fever (\>38.0 ℃) within 72 hours following vaccination * Oral temperature \>38.0 ℃ at the vaccination day * Erythema, tattoo, injury at shoulder (vaccination site) * Influenza vaccination within 6months * Any vaccination within 30 days * Concomitant medications/therapy such as immunosuppressants or immune modifying drugs, systemic corticosteroids, immunoglobulins, blood or blood- derived products, or anti-cancer chemotherapy or radiation therapy within3 months * Pregnant or breast-feeding women * Clinically significant underlying diseases or medical history at investigator's discretion